Background: Brain atrophy has shown a protective effect on the risk of early neurological deterioration (END) related to malignant edema in patients with hemispheric infarction but could be deleterious on the outcome. Aims: We aimed to assess whether brain atrophy has an impact on the risk of END and on the outcome in severe ischemic strokes after intravenous (IV) thrombolysis. Methods: From a prospective thrombolysis registry, 137 patients who had a National Institutes of Health Stroke Scale (NIHSS) ≥15, MRI at admission, and IV thrombolysis were included. Relative cerebral volume was calculated. END was defined as a ≥2-points deterioration 72-h NIHSS and a good outcome as a modified Rankin Scale (mRS) ≤2 at 3 months. A multiple logistic regression analysis with a stepwise backward procedure was performed. Results: END and a good outcome were observed, respectively, in 20 (14.6%) and 48 (37.5%) patients. In univariate analysis, predictors of END included age (p = 0.049), diabetes (p = 0.041), and parenchymal hemorrhage (p = 0.039). In multivariate analysis, age (p = 0.018) was significantly associated with END. Brain atrophy was not associated with END even in subgroup analysis according to the baseline infarct size. In univariate analysis, age (p = 0.003), prestroke mRS (p = 0.002), hypertension (p = 0.006), baseline NIHSS (p = 0.002), END (p = 0.002), proximal occlusion (p = 0.006), and recanalization at 24 h (p < 0.001) were associated with a good outcome. Only baseline NIHSS (p = 0.006) was associated with a good outcome after adjustment. Conclusions: We did not find any impact of brain atrophy on the risk of END and the outcome at 3 months in severe ischemic strokes after IV thrombolysis.

Keywords:
Stroke, Thrombolytic therapy, Early neurologic deterioration, Brain atrophy
1.
Beck C, Kruetzelmann A, Forkert ND, et al: A simple brain atrophy measure improves the prediction of malignant middle cerebral artery infarction by acute DWI lesion volume. J Neurol 2014; 261: 1097–1103.
2.
Minnerup J, Wersching H, Ringelstein EB, et al: Prediction of malignant middle cerebral artery infarction using computed tomography-based intracranial volume reserve measurements. Stroke 2011; 42: 3403–3409.
3.
Park J, Goh DH, Sung JK, Hwang YH, Kang DH, Kim Y: Timely assessment of infarct volume and brain atrophy in acute hemispheric infarction for early surgical decompression: strict cutoff criteria with high specificity. Acta Neurochir (Wien) 2012; 154: 79–85.
4.
Lee SH, Oh CW, Han JH, et al: The effect of brain atrophy on outcome after a large cerebral infarction. J Neurol Neurosurg Psychiatry 2010; 81: 1316–1321.
5.
Laurencin C, Philippeau F, Blanc-Lasserre K, et al: Thrombolysis for acute minor stroke: outcome and barriers to management. Results from the RESUVAL stroke network. Cerebrovasc Dis 2015; 40: 3–9.
6.
Adams HP, Davis PH, Leira EC, et al: Baseline NIH stroke scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in acute stroke treatment (TOAST). Neurology 1999; 53: 126–131.
7.
Mazya MV, Lees KR, Collas D, et al: IV thrombolysis in very severe and severe ischemic stroke: results from the SITS-ISTR registry. Neurology 2015; 85: 2098–2106.
8.
Adams HP, Bendixen BH, Kappelle LJ, et al: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 1993; 24: 35–41.
9.
Siegler JE, Boehme AK, Kumar AD, Gillette MA, Albright KC, Martin-Schild S: What change in the National Institutes of Health Stroke Scale should define neurologic deterioration in acute ischemic stroke? J Stroke Cerebrovasc Dis 2013; 22: 675–682.
10.
Smith SM: Fast robust automated brain extraction. Hum Brain Mapp 2002; 17: 143–155.
11.
Herweh C, Prager E, Sykora M, Bendszus M: Cerebral atrophy is an independent risk factor for unfavorable outcome after spontaneous supratentorial intracerebral hemorrhage. Stroke 2013; 44: 968–971.
12.
Fedorov A, Beichel R, Kalpathy-Cramer J, et al: 3D Slicer as an image computing platform for the quantitative imaging network. Magn Reson Imaging 2012; 30: 1323–1341.
13.
Wardlaw JM, Smith EE, Biessels GJ, et al: Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12: 822–838.
14.
Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA: MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol 1987; 149: 351–356.
15.
Zaidat OO, Yoo AJ, Khatri P, et al: Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke 2013; 44: 2650–2663.
16.
Hacke W, Kaste M, Fieschi C, et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017–1025.
17.
Thomalla G, Hartmann F, Juettler E, et al: Prediction of malignant middle cerebral artery infarction by magnetic resonance imaging within 6 hours of symptom onset: a prospective multicenter observational study. Ann Neurol 2010; 68: 435–445.
18.
Seners P, Turc G, Oppenheim C, Baron JC: Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implications. J Neurol Neurosurg Psychiatry 2015; 86: 87–94.
19.
Mori M, Naganuma M, Okada Y, et al: Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the stroke acute management with urgent risk factor assessment and improvement rt-PA registry. Cerebrovasc Dis 2012; 34: 140–146.
20.
Kim JT, Park MS, Chang J, Lee JS, Choi KH, Cho KH: Proximal arterial occlusion in acute ischemic stroke with low NIHSS scores should not be considered as mild stroke. PLoS One 2013; 8:e70996.
21.
Jeong HG, Kim BJ, Yang MH, Han MK, Bae HJ: Neuroimaging markers for early neurologic deterioration in single small subcortical infarction. Stroke 2015; 46: 687–691.
22.
Simonsen CZ, Schmitz ML, Madsen MH, et al: Early neurological deterioration after thrombolysis: clinical and imaging predictors. Int J Stroke 2016; 11: 776–782.
23.
Seners P, Turc G, Tisserand M, et al: Unexplained early neurological deterioration after intravenous thrombolysis: incidence, predictors, and associated factors. Stroke 2014; 45: 2004–2009.
24.
Dávalos A, Toni D, Iweins F, Lesaffre E, Bastianello S, Castillo J: Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European cooperative acute stroke study (ECASS) I. Stroke 1999; 30: 2631–2636.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.